• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ADMA Biologics Inc - Common Stock (NQ:ADMA)

    8.270 -0.230 (-2.71%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 3,718,909
    Open 8.480
    Bid (Size) 8.240 (100)
    Ask (Size) 8.280 (100)
    Prev. Close 8.500
    Today's Range 8.200 - 8.535
    52wk Range 7.210 - 22.37
    Shares Outstanding 196,357,149
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Lowey Dannenberg, P.C. is Investigating ADMA Biologics (NASDAQ: ADMA) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the Firm
    From Lowey Dannenberg, P.C.
    Via GlobeNewswire
    ADMA Biologics (NASDAQ:ADMA) Shares Plunge on Q1 Miss and Revenue Guidance Cut ↗
    Via Chartmill

    Performance

    YTD
    -53.7%
    -53.7%
    1 Month
    -23.0%
    -23.0%
    3 Month
    -48.2%
    -48.2%
    6 Month
    -46.4%
    -46.4%
    1 Year
    -58.0%
    -58.0%

    More News

    Read More
    News headline image
    ADMA (ADMA) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
    From The Rosen Law Firm PA
    Via GlobeNewswire
    What's going on in today's after hours session ↗
    Via Chartmill
    News headline image
    ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    News headline image
    ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    News headline image
    ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Continues – Shareholders Who Lost Money Urged to Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
    From Glancy Prongay Wolke & Rotter LLP
    Via Business Wire
    News headline image
    ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
    From Law Offices of Howard G. Smith
    Via Business Wire
    News headline image
    Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    News headline image
    ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    ADMA Biologics (NASDAQ: ADMA) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.
    From Lowey Dannenberg, P.C.
    Via GlobeNewswire
    News headline image
    ADMA Fraud Notice: ADMA Biologics Investors are Notified the Company is being Investigated for Securities Fraud after 29% Stock Drop — BFA Law
    From Bleichmar Fonti & Auld LLP
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    ADMA INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving ADMA Biologics, Inc.
    From Kirby McInerney LLP
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADMA Biologics, Inc. – ADMA
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    ADMA SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
    From Kirby McInerney LLP
    Via GlobeNewswire
    News headline image
    ADMA BIOLOGICS, INC. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
    From Kirby McInerney LLP
    Via Business Wire

    Frequently Asked Questions

    Is ADMA Biologics Inc - Common Stock publicly traded?
    Yes, ADMA Biologics Inc - Common Stock is publicly traded.
    What exchange does ADMA Biologics Inc - Common Stock trade on?
    ADMA Biologics Inc - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for ADMA Biologics Inc - Common Stock?
    The ticker symbol for ADMA Biologics Inc - Common Stock is ADMA on the Nasdaq Stock Market
    What is the current price of ADMA Biologics Inc - Common Stock?
    The current price of ADMA Biologics Inc - Common Stock is 8.270
    When was ADMA Biologics Inc - Common Stock last traded?
    The last trade of ADMA Biologics Inc - Common Stock was at 05/15/26 04:00 PM ET
    What is the market capitalization of ADMA Biologics Inc - Common Stock?
    The market capitalization of ADMA Biologics Inc - Common Stock is 1.62B
    How many shares of ADMA Biologics Inc - Common Stock are outstanding?
    ADMA Biologics Inc - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.